[field view] Ge Rui: biomedical development, cooperation opportunities between UK and China

The UK's universal medical service system is well-known in the world, while the development speed and depth of China's pharmaceutical market in the past are quite amazing China's clinical trials and drug standards have gradually been in line with the international standards China and the UK have broad cooperation space from new drug research and development, clinical trials to the medical system, and it is at the right time to promote China UK medical cooperation On the cooperation between China and the UK, Mr Ge Rui, deputy director of life science and health in China of the Ministry of international trade and business consul of the British Consulate General in Chongqing, introduced British international through the report "development of British biomedicine and opportunities for UK China cooperation" at the 2019 China Pharmaceutical and health Industry Development Conference and the fourth China Pharmaceutical R & D Innovation Summit (PDI Conference) The Ministry of trade ("DIT") and its services for the cooperation between Chinese and British enterprises In addition, Mr Gerry focuses on the vigorous development of the British life science industry, and particularly explains that the industry currently has the best investment opportunities 01 Introduction to the organization and functions of the British Department of international trade UKTI was before 2016 After the brexit in 2016, UKTI was promoted to be the ministerial Department of the British government, which is now the British Department of international trade (DIT) This department is mainly to seek opportunities for Global trade cooperation and help all foreign companies to carry out business, take root and grow in the UK The UK Department of international trade can provide diversified services for each investment institution, mainly due to its unique institutional setting There are working groups in every industry of DIT As the working group of life sciences, it is divided into five parts: the first part is to invest in the UK, set up companies, including the expansion of the company's business in the UK, or direct equity investment; the second part is technology transfer It can be done mainly in medicine and medical technology Because the basic research in the UK is relatively strong, many start-ups and small and medium-sized enterprises have been incubated, and the cooperation between these enterprises and China's technology transfer has been very active in recent years The third sector is licensing There are many innovative new drugs in the UK, as well as generics and biopharmaceuticals, which are opportunities We can cooperate with China The fourth sector is distribution When Chinese enterprises sell products to the UK and even the whole Europe, DIT will suggest that they find a local partner, or establish a joint venture or wholly-owned company with local partners The fifth sector is R & D services Throughout the UK investment process, DIT will provide a number of flexible services, including a full range of consulting services In addition, the global DIT team will provide you with the latest and most reliable business wisdom DIT's services will not be limited to the establishment of business, but will be accompanied by the entire life cycle of investment enterprises in the UK So far, the UK Department of international trade has helped thousands of foreign enterprises to take root in the UK and accumulated rich experience At the same time, through the help of these enterprises, we can learn their opinions or suggestions, and further improve the service quality of DIT In addition to DIT, the UK Department of international trade, service trade teams in England, Scotland and Wales, as well as local incubators and industry associations in the UK can provide services for investment enterprises DIT's all-round service is one of the conditions to attract investment enterprises to settle in the UK, but the most important thing is that the choice of investment is based on the industry prospect, project value, risk and other evaluation factors Therefore, Mr Ge Rui cited several sets of data and potential enterprises to explain that the life science industry currently has the best investment opportunity 02 Investment prospects of life science industry in the UK In the industry of life science in the UK, Boston and San Francisco are called the three industry clusters The industry of life science in the UK is the third pillar industry, with more than 240000 staff In the past six years, the number of patients participating in clinical trials in the UK has reached 300, and the number of clinical trials supported by the industry foundation has increased by 500% in the past few years Academically speaking, life science in the UK The academic industry has Nobel laureates On this basis, the UK has also put forward two plans in the life science industry, namely, one is the world's first human genome project of 1 million in the next five years, of which 500000 are from the UK's medical system and 500000 are from the UK's biological bank The second is the UK's strategic adjustment fund of £ 146 million to support the research, development and production of life science and medicine, which helps the UK become the center of therapeutic therapy around the world The UK usually divides the life science industry into two major sectors, one is biomedicine, and the other is medical technology From the perspective of human resources, the two sectors are equally competitive In terms of output value, the GDP contributed by the whole biomedical industry accounts for nearly 70% The top 25% of the world's GDP is operated by entities, and the number of employees accounts for 25% of the whole industry The GDP generated by medical technology accounts for 38% of the whole industry Among these two sectors, biomedicine is the largest one in the UK life science industry It now has 2150 companies with annual GDP of nearly £ 50 billion The biomedical industry has been booming, mainly due to the UK's large number of scientists and talents, advanced clinical trial and technology platform, NHS database, etc In addition, the advantages of the British biomedical sector are also reflected in the precise control of drug characteristics This part is from the UK before brexit, most of the UK employees who worked in the European drug administration have a very accurate grasp of drug levy, and the other part is the start-up companies that control drug levy in the forefront For example, videregen mainly provides organs for clinical trial, including transplantation and storage of tissues At present, it has business cooperation with the UK, EU and many Asian countries There are also a number of companies worthy of investment, such as clinigen, lifearc, which has many research experts, PCI, which focuses on clinical trial outsourcing Statement: this opinion only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.